PubMed HealthSearch

Biomedical subjects

M Selimov

Publications and source records attributed to M Selimov.

3 recordsLinked to original sources

Comparison studies on potency tests for rabies vaccines.

Eleven laboratories from eight countries and four continents took part in a collaborative study to evaluate experimental procedures to be used in selecting the new standard reference rabies vaccine prepared in human diploid cell cultures. The following procedures were used : (a) the NIH potency test in mice, (b) the antibody binding technique (by either mouse inoculation or the tissue culture method), (c) virus-neutralizing antibody levels in mice used for the NIH test, and (d) antibody induction in human volunteers treated with vaccine alone and in combination with human rabies gamma globulin. The four methods used for determination of rabies antibodies were mouse inoculation, rapid fluorescent focus inhibition, plaque reduction and complement fixation techniques. All results were expressed in International Units as compared to the standard WHO serum and vaccine preparations. In general, a close correlation was noted in results from different laboratories, and it was recommended that the future rabies standard vaccine should be evaluated by three testing procedures, the NIH test, the antibody-binding technique, and antibody levels in mice used for the NIH test.

Animals

Serological investigations on rabies tissue culture vaccine (USSR) and development of short methods in post-exposure treatment.

Comparisons have been carried out in the GDR between the Hempt-vaccine, which has been used until now, and a vaccine prepared in the USSR from the Vnukovo-32 strain on tissue culture. A trial of 1,800 treatments undertaken in 18 vaccination centres has clearly shown that the tissue culture vaccine is superior to the Hempt-vaccine and allows the number of injections to be reduced. The authors recommend three types of treatment--with or without the combination of antirabies immunoglobulin--according to the risk of exposure or the injuries sustained.

Antibody Formation

Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain. Results of its industrial production and field use for post-exposure immunization of man.

During 1973-1977, 981,000 doses of rabies vaccine were prepared in primary young Syrian hamster kidney cell cultures infected with attenuated rabies virus (strain Vnukovo-32) and inactivated by UV-irradiation. Potency of the vaccine varied from 0.3 to 3.5. More the 53% of vaccine lots had potency in the range of 1.1-3.5 (NIH). Post-exposure immunization was carried out in 45,842 persons aged from 2 weeks to greater than 76 years. The vaccination course lasted from 2 to 25 days and was followed by 2 booster injections with the dose of 1.5-5 ml. The vaccine combined with gammaglobulin was injected into 2,856 persons; 19,764 persons had bites of dangerous localization (face, head, fingers). Post-exposure immunization was carried out in 4,416 humans who were bitten or licked with saliva of rabid animals (diagnosis was confirmed clinically or in the laboratory) and in 16,760 humans bitten by suspected animals (diagnosis remained unknown). None of those who received the complete course of antirabic treatment fell ill with hydrophobia. No neurological complications or other severe side effects were noted. Field trials and the results of studies of virus-neutralizing antibody titers in 390 treated people make it possible to conclude that tissue culture rabies vaccine from strain Vnukovo-32 is an effective preparation with low reactogenicity.

Adolescent